(Sharecast News) - IP Group announced on Thursday that its portfolio company Istesso has published peer-reviewed data demonstrating that its new class of oral investigational medicines could promote tissue repair in fibrotic, autoinflammatory, and autoimmune diseases - a first for oral agents in these therapeutic areas.
The study, published in the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE